Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult ≥18 years of age~2. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other authorized or approved assay in any specimen collected within 72 hours prior to enrollment.~   Note - An exception must be requested to the Sponsor if ≥72 hours since positive test.~3. Hospitalized in participating facility.~4. Documentation of pneumonia with radiographic evidence of infiltrates by imaging (e.g., chest x-ray or CT scan).~5. Abnormal respiratory status that is judged worse than baseline by the investigator and as documented at any point within 24 hours prior to randomization, consistent with ordinal scale levels 5, 6 or 7, specifically defined as:~   * Room air saturation of oxygen (SaO2) \< 93%, OR~  * Requiring supplemental oxygen, OR~  * Tachypnea with respiratory rate ≥30~6. Patient or proxy is willing and able to provide written informed consent and comply with all protocol requirements~Exclusion Criteria:~1. Contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator.~2. Clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than COVID-19~3. Receipt of other investigational therapy as a part of another clinical trial. Note: investigational therapies used as part of clinical care, (eg, remdesivir, hydroxychloroquine) are permissible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COVID-19 Convalescent plasma (Type: EXPERIMENTAL): COVID-19 Convalescent plasma on Study Day 1 in addition to standard care
- Standard care (Type: NO_INTERVENTION): Standard care alone

Based on this trial design, predict the completion outcome and termination type (if applicable).